Cory Kasimov

In a report published Thursday, J.P. Morgan analyst Cory Kasimov reiterated an Overweight rating on Keryx Biopharmaceuticals (NASDAQ: KERX), and raised the price target from $14.00 to $22.00. In the report, J.P. Morgan noted, “Yesterday's impressive data in NDD-CKD patients highlights Zerenex's...

In a report published Friday, J.P. Morgan analyst Cory Kasimov initiated coverage on Isis Pharmaceuticals (NASDAQ: ISIS) with a Neutral rating and $37.00 price target. In the report, J.P. Morgan noted, “We are initiating coverage of Isis Pharmaceuticals with a Neutral rating. The company is well...

In a report published Thursday, J.P. Morgan analyst Cory Kasimov initiated coverage on Pharmacyclics (NASDAQ: PCYC) with an Overweight rating and $142.00 price target. In the report, J.P. Morgan noted, “We are initiating coverage of Pharmacyclics with an Overweight rating based on the potential of...

In a report published on Monday, J.P. Morgan analyst Cory Kasimov initiated coverage on bluebird bio (NASDAQ: BLUE) with an Overweight rating and a $44 price target. In the report, J.P. Morgan stated, "Catchy titles aside, bluebird bio is anything but “Old School.” Quite the contrary. In our...

In a report published on Wednesday, J.P. Morgan analyst Cory Kasimov initiated coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a rating of Overweight and a price target of $13. In the report, J.P. Morgan stated, "We are initiating coverage of Keryx Biopharmaceuticals...based on the...

In a report published Tuesday, J.P. Morgan analyst Cory Kasimov downgraded the rating on Rigel Pharmaceuticals (NASDAQ: RIGL) from Overweight to Neutral. In the report, J.P. Morgan noted, “We are downgrading RIGL shares to Neutral (from OW) following AZN's decision to return the rights for RIGL...

In a report published Wednesday, J.P. Morgan analyst Cory Kasimov reiterated an Overweight rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised the price target from $48.00 to $69.00. In the report, J.P. Morgan noted, “We are continuing our ‘Doc Rounds' series wherein we speak with a...

Orexigen Therapeutics (NASDAQ: OREX) was upgraded from Neutral to Overweight with a $10 price target by J.P. Morgan on Thursday following FDA approval of the drug Belviq (lorcaserin). Arena Pharmaceuticals (NASDAQ: ARNA) scored a big hit this week after this decision to approve the obesity drug...

JP Morgan's biotech analysts Cory Kasimov, Mona Ashiya, and Karen Jay rate Ariad Pharmaceuticals (NASDAQ: ARIA) Overweight. Ariad's updated Phase I results for new cancer drug AP-23534 were presented on 6/3, and were promising. There were no signals for safety issue either. Based on these results,...

J.P. Morgan analysts Cory Kasimov and Mona Ashiya reiterated their Overweight rating for shares of Human Genome Sciences, Inc. (Nasdaq: HGSI) The two analysts believed that the failure of a recent Phase 2 non-small cell lung cancer trial would not have a significant impact on Human Genome Sciences...